"Middle Aged" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
No definition found.
Descriptor ID |
D008875
|
MeSH Number(s) |
M01.060.116.630
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Middle Aged".
Below are MeSH descriptors whose meaning is more specific than "Middle Aged".
This graph shows the total number of publications written about "Middle Aged" by people in this website by year, and whether "Middle Aged" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 0 | 171 | 171 |
1995 | 0 | 220 | 220 |
1996 | 0 | 235 | 235 |
1997 | 0 | 238 | 238 |
1998 | 0 | 274 | 274 |
1999 | 0 | 249 | 249 |
2000 | 0 | 326 | 326 |
2001 | 0 | 303 | 303 |
2002 | 0 | 336 | 336 |
2003 | 0 | 382 | 382 |
2004 | 0 | 386 | 386 |
2005 | 0 | 469 | 469 |
2006 | 0 | 555 | 555 |
2007 | 0 | 542 | 542 |
2008 | 0 | 661 | 661 |
2009 | 0 | 604 | 604 |
2010 | 0 | 671 | 671 |
2011 | 0 | 768 | 768 |
2012 | 0 | 780 | 780 |
2013 | 0 | 814 | 814 |
2014 | 0 | 808 | 808 |
2015 | 0 | 871 | 871 |
2016 | 0 | 902 | 902 |
2017 | 0 | 908 | 908 |
2018 | 0 | 967 | 967 |
2019 | 0 | 1018 | 1018 |
2020 | 0 | 866 | 866 |
2021 | 0 | 651 | 651 |
2022 | 0 | 154 | 154 |
2023 | 0 | 216 | 216 |
2024 | 0 | 474 | 474 |
To return to the timeline,
click here.
Below are the most recent publications written about "Middle Aged" by people in Profiles.
-
Optimizing the post-CAR T monitoring period in recipients of axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel. Blood Adv. 2024 Oct 22; 8(20):5346-5354.
-
Beat-AML 2024 ELN-refined risk stratification for older adults with newly diagnosed AML given lower-intensity therapy. Blood Adv. 2024 Oct 22; 8(20):5297-5305.
-
MEN1/DAXX/ATRX mutations enhance progression-free survival in gastroenteropancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy. Endocr Relat Cancer. 2024 Nov 01; 31(11).
-
Real-World Persistence of Successive Biologics in Patients With Inflammatory Bowel Disease: Findings From ROTARY. Inflamm Bowel Dis. 2024 Oct 03; 30(10):1776-1787.
-
Characteristics of a cost-effective blood test for colorectal cancer screening. J Natl Cancer Inst. 2024 Oct 01; 116(10):1612-1620.
-
Social Vulnerability and Prevalence and Treatment for Mental Health and Substance Use Disorders. JAMA Psychiatry. 2024 Oct 01; 81(10):976-984.
-
Which Social Variables Predict Diabetes Onset? Robust Findings in Two National Surveys. Gerontologist. 2024 Oct 01; 64(10).
-
Abiraterone, Olaparib, or Abiraterone + Olaparib in First-Line Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects (BRCAAway). Clin Cancer Res. 2024 Oct 01; 30(19):4318-4328.
-
Prevention, Diagnosis, and Treatment of Hepatocellular Carcinoma. JAMA. 2024 Sep 24; 332(12):1013-1014.
-
Impact of a health-system specialty pharmacy on time to upadacitinib initiation. Am J Health Syst Pharm. 2024 Sep 23; 81(19):e594-e600.